Gynecologic Cancer
Conference Coverage
DEI training gives oncology fellows more confidence
Only 2%-3% of practicing oncologists are Black or Hispanic/Latino, says Yale Cancer Center doctor.
Feature
Drugmakers are abandoning cheap generics, and now U.S. cancer patients can’t get meds
On Nov. 22, three FDA inspectors arrived at the sprawling Intas Pharmaceuticals plant south of Ahmedabad, India, and found hundreds of trash bags...
Conference Coverage
ACS officer provides ASCO highlights: Targeting hidden cancer, AI in oncology
A pair of new studies show that drugs can reduce cancer risk when cells are elusive.
Feature
Widespread carboplatin, cisplatin shortages: NCCN survey
Only 64% of centers said they are still able to continue treating all current patients receiving carboplatin.
From the Journals
Ovarian cancer: Sequencing strategy identifies biomarker that could guide treatment
Novel sequencing strategy appears to be a reliable predictor of homologous recombination DNA repair deficiency.
Conference Coverage
Antibody-drug conjugate changes standard of care for platinum-resistant ovarian cancer
A novel therapy has a favorable safety profile, and more like it may be on the way.
Conference Coverage
Up-front pembro plus chemo boost survival in cervical cancer
Adding immunotherapy resulted in a 40% reduction in risk of death, compared with chemotherapy alone, for women with advanced cervical cancers...
Conference Coverage
‘Huge step forward’ in advanced ovarian cancer
A preplanned interim analysis revealed that the addition of durvalumab and olaparib was associated with a 37% improvement of PFS, compared with...
Conference Coverage
Surgical de-escalation passes clinical test in low-risk cervical cancer
‘Practice-changing’ results could reduce long-term survivor effects among qualifying patients.
From the Journals
Mailed HPV test kits boost cervical cancer screening
About 23% of eligible women are overdue for cervical cancer screening by at least a year.
From the Journals
Number of cancer survivors with functional limitations doubled in 20 years
The 70% prevalence of functional limitation among survivors in 2018 is nearly twice that of the general population.